NASDAQ:IMMU - Immunomedics Stock Price, News, Headlines & Rumors

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics, Inc. (NASDAQ:IMMU) posted its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analyst estimates of $4.27 million. The firm's revenue was down 61.5% compared to the same quarter last year. View Immunomedics' Earnings History.

3 analysts have issued twelve-month price objectives for Immunomedics' stock. Their forecasts range from $27.00 to $53.00. On average, they expect Immunomedics' share price to reach $37.00 in the next twelve months. This suggests a possible upside of 74.4% from the stock's current price. View Analyst Price Targets for Immunomedics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.

Immunomedics saw a drop in short interest in July. As of July 31st, there was short interest totalling 16,963,631 shares, a drop of 15.9% from the July 13th total of 20,165,241 shares. Based on an average daily trading volume, of 1,942,013 shares, the days-to-cover ratio is presently 8.7 days. Currently, 10.8% of the company's stock are short sold. View Immunomedics' Current Options Chain.

Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML) and ImmuCell (ICCC).

News stories about IMMU stock have trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Immunomedics earned a news impact score of 0.19 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 46.25 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Immunomedics.

Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.71%), FMR LLC (5.08%), SEATTLE GENETICS INC (4.90%), Orbimed Advisors LLC (2.95%), Acuta Capital Partners LLC (2.84%) and Millennium Management LLC (2.24%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Orbimed Advisors LLC, DAFNA Capital Management LLC, First Trust Advisors LP, Wells Fargo & Company MN, Alps Advisors Inc., PNC Financial Services Group Inc. and EAM Global Investors LLC. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

IMMU stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, BlackRock Inc., American Century Companies Inc., Voya Investment Management LLC, Janus Henderson Group PLC, Millennium Management LLC, FMR LLC and Menora Mivtachim Holdings LTD.. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $21.22.

Immunomedics has a market capitalization of $3.95 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]